Edward P. Feener net worth and biography

Edward Feener Biography and Net Worth

Ed is a co-founder of KalVista and joined as Chief Scientific Officer in 2016. Previously, Dr. Feener was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center. He has 30 years of research experience in vascular biology and diabetic complications. His laboratory has performed pioneering research on the kallikrein kinin system and was first to identify plasma kallikrein as a potential therapeutic target for diabetic macular edema. Ed has published over 80 scientific articles and has served on multiple national and international scientific research review committees.

Ed received his PhD in Biochemistry from Boston University and completed postdoctoral training at the Joslin Diabetes Center and Harvard Medical School.

What is Edward P. Feener's net worth?: The estimated net worth of Edward P. Feener is at least $869,195.94 as of May 20th, 2024. Dr. Feener owns 72,858 shares of KalVista Pharmaceuticals stock worth more than $869,196 as of March 30th. This net worth evaluation does not reflect any other assets that Dr. Feener may own. Learn More about Edward P. Feener's net worth.
How do I contact Edward P. Feener?: The corporate mailing address for Dr. Feener and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at ir@kalvista.com. Learn More on Edward P. Feener's contact information.
Has Edward P. Feener been buying or selling shares of KalVista Pharmaceuticals?: Edward P. Feener has not been actively trading shares of KalVista Pharmaceuticals during the last quarter. Most recently, Edward P. Feener sold 8,088 shares of the business's stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.76, for a transaction totalling $95,114.88. Following the completion of the sale, the insider now directly owns 72,858 shares of the company's stock, valued at $856,810.08. Learn More on Edward P. Feener's trading history.
Who are KalVista Pharmaceuticals' active insiders?: KalVista Pharmaceuticals' insider roster includes Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Michael Smith (VP), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.
Are insiders buying or selling shares of KalVista Pharmaceuticals?: During the last year, KalVista Pharmaceuticals insiders bought shares 5 times. They purchased a total of 236,055 shares worth more than $2,162,146.35. During the last year, insiders at the specialty pharmaceutical company sold shares 15 times. They sold a total of 117,899 shares worth more than $1,300,246.77. The most recent insider tranaction occured on March, 7th when CEO Benjamin L Palleiko sold 6,669 shares worth more than $79,827.93. Insiders at KalVista Pharmaceuticals own 10.5% of the company. Learn More about insider trades at KalVista Pharmaceuticals.
Information on this page was last updated on 3/7/2025.

Edward P. Feener Insider Trading History at KalVista Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/20/2024	Sell	8,088	$11.76	$95,114.88	72,858
2/20/2024	Sell	28,288	$14.07	$398,012.16	62,157
1/11/2024	Sell	22,679	$13.03	$295,507.37	39,828
1/8/2024	Sell	17,221	$13.01	$224,045.21	62,607
11/1/2021	Sell	6,000	$18.07	$108,420.00
7/23/2019	Sell	3,300	$18.62	$61,446.00	98,634
4/17/2019	Sell	4,000	$24.92	$99,680.00	100,950
1/16/2019	Sell	4,000	$19.55	$78,200.00	106,334

Edward P. Feener Buying and Selling Activity at KalVista Pharmaceuticals

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $11.93

$11.82

$12.50

50 Day Range

MA: $10.56

$8.30

$12.60

2 Week Range

Now: $11.93

$7.30

$15.50

Volume

275,700 shs

Average Volume

386,462 shs

Market Capitalization

$593.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76